Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...

No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as ...

Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, ...

What a CEO makes can be staggering from the seat of a rank-and-file employee, whose pay is typically in the five-to-six digit ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

When it comes to vaccination, the COVID-19 pandemic divided American society. President Donald Trump and his new Health and ...